168 related articles for article (PubMed ID: 34764465)
1. The importance of persistence in cancer drug development.
Mullard A
Nat Rev Drug Discov; 2021 Dec; 20(12):890-891. PubMed ID: 34764465
[No Abstract] [Full Text] [Related]
2. Trastuzumab Deruxtecan: First Approval.
Keam SJ
Drugs; 2020 Apr; 80(5):501-508. PubMed ID: 32144719
[TBL] [Abstract][Full Text] [Related]
3. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
4. Targeting the human kinome for cancer therapy.
Daly RJ
Crit Rev Oncog; 2012; 17(1):vi-vii. PubMed ID: 22471667
[No Abstract] [Full Text] [Related]
5. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab Deruxtecan DESTINY for Some Cancers.
Cancer Discov; 2020 Jul; 10(7):898. PubMed ID: 32487568
[TBL] [Abstract][Full Text] [Related]
8. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
9. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
10. Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic.
Oo C; Ameer B
Drug Discov Today; 2021 Jun; 26(6):1337-1339. PubMed ID: 33932595
[TBL] [Abstract][Full Text] [Related]
11. Current trends in the treatment of HR+/HER2+ breast cancer.
Kay C; Martínez-Pérez C; Meehan J; Gray M; Webber V; Dixon JM; Turnbull AK
Future Oncol; 2021 May; 17(13):1665-1681. PubMed ID: 33726508
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
[TBL] [Abstract][Full Text] [Related]
13. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
14. Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa).
Med Lett Drugs Ther; 2020 Nov; 62(1611):182-184. PubMed ID: 33429416
[No Abstract] [Full Text] [Related]
15. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
16. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
[No Abstract] [Full Text] [Related]
17. [Role in oncology and targeting of the PTK7 tyrosine kinase receptor].
Ganier L; Morelli X; Borg JP
Med Sci (Paris); 2020 Oct; 36 Hors série n° 1():42-46. PubMed ID: 33052093
[No Abstract] [Full Text] [Related]
18. The RACE to accelerate drug development for children with cancer.
Pearson ADJ; Karres D; Reaman G; DuBois SG; Knox L; Scobie N; Vassal G
Lancet Child Adolesc Health; 2020 Oct; 4(10):714-716. PubMed ID: 32822672
[No Abstract] [Full Text] [Related]
19. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
20. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
Yver A; Agatsuma T; Soria JC
Ann Oncol; 2020 Mar; 31(3):430-434. PubMed ID: 32067685
[No Abstract] [Full Text] [Related]
[Next] [New Search]
